OpenURL Connection Search

Select item for more details and to access through your institution.

P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S124, doi. 10.1016/S2152-2650(21)02289-8
By:
- Delforge, Michel;
- Raddoux, Jolien;
- Kenis, Cindy;
- Vanhellemont, Anneleen;
- Mineur, Philippe;
- Hoornaert, Ellen;
- Ka Lung Wu;
- Caers, Jo;
- Eygen, Koen Van;
- Kentos, Alain;
- Depaus, Julien;
- Put, Natalie;
- Van De Velde, Ann;
- Claes, Géraldine;
- Vlummens, Philip;
- Maertens, Vincent;
- Meuleman, Nathalie;
- Broek, Isabelle Vande;
- Vaes, Mélanie;
- Fostier, Karel
Publication type:
Article
What matters most to patients with multiple myeloma? A Pan-European patient preference study.
Published in:
Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.1027353
By:
- Janssens, Rosanne;
- Lang, Tamika;
- Vallejo, Ana;
- Galinsky, Jayne;
- Morgan, Kate;
- Plate, Ananda;
- Ronne, Chris De;
- Verschueren, Margaux;
- Schoefs, Elise;
- Vanhellemont, Anneleen;
- Delforge, Michel;
- Schjesvold, Fredrik;
- Cabezudo, Elena;
- Vandebroek, Martina;
- Stevens, Hilde;
- Simoens, Steven;
- Huys, Isabelle
Publication type:
Article
Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.
Published in:
OncoTargets & Therapy, 2022, v. 15, p. 243, doi. 10.2147/OTT.S341120
By:
- Delforge, Michel;
- Raddoux, Jolien;
- Antonis, Corine;
- Clement, Céline;
- Kint, Nicolas;
- Vanhellemont, Anneleen;
- Bravetti, Julie;
- Vandenberghe, Peter
Publication type:
Article

Found: 3

P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients.

What matters most to patients with multiple myeloma? A Pan-European patient preference study.

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.